Type(s) of biological/targeted therapy-Lenalidomide Posts on Medivizor
Navigation Menu

Type(s) of biological/targeted therapy-Lenalidomide Posts on Medivizor

How does daratumumab with lenalidomide and dexamethasone impact the quality of life of patients with multiple myeloma?

How does daratumumab with lenalidomide and dexamethasone impact the quality of life of patients with multiple myeloma?

Posted by on Dec 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the impact of the D-Rd regimen including daratumumab (Darzalex) combined with lenalidomide (Revlimid) and dexamethasone (Decadron) on the quality of life of patients with multiple myeloma (MM) who cannot undergo a transplant. The study showed that patients who received D-Rd reported lower levels of...

Read More

Pomalidomide, bortezomib and dexamethasone for multiple myeloma relapsed after lenalidomide treatment

Pomalidomide, bortezomib and dexamethasone for multiple myeloma relapsed after lenalidomide treatment

Posted by on Dec 13, 2020 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the outcomes for patients with multiple myeloma (MM) who were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (Decadron) after relapsing following lenalidomide (Revlimid) treatment.  This study concluded that this treatment combination was effective in...

Read More

Looking for patients with relapsed multiple myeloma to test a biological drug and immune cell vaccine

Posted by on Jul 31, 2019 in Multiple Myeloma | 0 comments

In a nutshell This trial is investigating the effectiveness and side effects of nivolumab (Opdivo) with a dendritic cell vaccine for patients with multiple myeloma (MM). The main outcome of this study would be to see the number of patients that develop an allergic reaction to the treatment. This study is recruiting in Boston, MA, United...

Read More

A combination of clarithromycin, pomalidomide and dexamethasone in patients with relapsed/unresponsive multiple myeloma

Posted by on Apr 12, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...

Read More

Minimal residual disease and its association with transplant success in Multiple Myeloma.

Posted by on Jan 27, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study monitored the development of minimal residual disease (MRD) after transplant for multiple myeloma (MM). The main finding was that different patterns of MRD development are associated with varying success after stem cell transplant for MM. Some background There are many treatments for MM. Patients are often cured fully by...

Read More

What is the benefit of adding ixazomib to lenalidomide and dexamethasone for relapsing/refractory multiple myeloma?

Posted by on Jul 3, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the effects of adding ixazomib (Ninlaro) to lenalidomide (Revlimid) and dexamethasone (Dexasone) for patients with unresponsive multiple myeloma. The main finding was that patients receiving ixazomib plus lenalidomide and dexamethasone survived longer without worsening of cancer (progression-free...

Read More

Carfilzomib – once weekly or twice weekly to treat unresponsive multiple myeloma?

Posted by on Jun 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...

Read More